top of page
Screen Shot 2023-04-27 at 3.10.34 PM.png

Chong Xu

F-Prime Capital Partner & K36 Board Member

Chong is a Partner at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime Chong has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and RareStone Group. Prior to joining F-Prime in 2015, Chong was a consultant with McKinsey and Company, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.


Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

bottom of page